Hologic (HOLX) Shares are Up 1.2%

Hologic (HOLX) : Traders are bullish on Hologic (HOLX) as it has outperformed the S&P 500 by a wide margin of 1.02% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.87%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.2% in the last 1 week, and is up 0.81% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 0.43% and the fifty day Moving Average is 5.78%. Hologic Inc. is up 12.76% in the last three month period. Year-to-Date the stock performance stands at 0.28%.

Hologic (HOLX) : Average target price received by Hologic (HOLX) is $42.39 with an expected standard deviation of $2.47. The most aggressive target on the stock is $46, whereas the most downbeat target is $39. 13 financial analysts are currently covering the stock.


Hologic (NASDAQ:HOLX): stock turned positive on Friday. Though the stock opened at $38.42, the bulls momentum made the stock top out at $39.14 level for the day. The stock recorded a low of $38.27 and closed the trading day at $38.8, in the green by 0.96%. The total traded volume for the day was 3,220,019. The stock had closed at $38.43 in the previous days trading.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.